Alector Study
Posted Date: May 29, 2020
- Investigator: Russell Sawyer
- Specialties:
- Type of Study: Drug
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations inthe Progranulin Gene
Criteria:
Please Contact The Study Contact For Further Details On The Eligibility Criteria
Keywords:
Frontotemporal Dementia, Dementia, Heterozygous Mutation
For More Information:
Kayla Stallworth
513-558-1707
stallwkj@ucmail.uc.edu